Dihua Yu
Impact in
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Cancer Research top 0.2%
- MicroRNA in disease regulation
Papers in
- Oncology 139
- HER2/EGFR in Cancer Research 57
- Cancer-related Molecular Pathways 36
- Peptidase Inhibition and Analysis 16
- Co-authors
- Mien‐Chie HungYi XiaoMing TanGabriel N. HortobágyiLin ZhangFrancisco J. EstevaSiyuan ZhangXiaoyan Zhou
- Journals
- Cancer Research (30 papers)Oncogene (14 papers)Cancer (7 papers)Cancer Cell (7 papers)Clinical Cancer Research (5 papers)
- Partner nations
- United StatesChinaTaiwan
In The Last Decade
Dihua Yu
237 papers receiving 18.7k citations
Hit Papers
Peers
Comparison fields: 5 of 165
- Oncology 9.0k
- Cancer Research 3.9k
- Molecular Biology 10.9k
- Radiology, Nuclear Medicine and Imaging 2.8k
- Immunology and Allergy 739
Countries citing papers authored by Dihua Yu
This map shows the geographic impact of Dihua Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dihua Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dihua Yu more than expected).
Fields of papers citing papers by Dihua Yu
This network shows the impact of papers produced by Dihua Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dihua Yu. The network helps show where Dihua Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Dihua Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 8 | |
| 3 | 2023 | 9 | |
| 4 | 2022 | 8 | |
| 5 | 2022 | 113 | |
| 6 | 2019 | 56 | |
| 7 | 2019 | 5 | |
| 8 | 2018 | 71 | |
| 9 | 2015 | 44 | |
| 10 | 2013 | 31 | |
| 11 | 2013 | 23 | |
| 12 | 2013 | 5 | |
| 13 | 2010 | 16 | |
| 14 | 2009 | 158 | |
| 15 | 2009 | 140 | |
| 16 | 2008 | 73 | |
| 17 | Early placenta insulin-like growth factor (pro-EPIL) is overexpressed and secreted by c-erbB-2-positive cells with high invasion potential. | 2002 | 20 |
| 18 | Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. | 2002 | 93 |
| 19 | E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. | 2000 | 82 |
| 20 | Effects of Sa-Mul-Tang on immunocytes of L1210 cells-transplanted or antitumor drugs-administered mice | 1998 | 2 |
About Dihua Yu
Dihua Yu is a scholar working on Oncology, Cancer Research, Biotechnology, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 242 papers that have together received 19.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (57 papers), Cancer-related Molecular Pathways (36 papers), Monoclonal and Polyclonal Antibodies Research (31 papers), Virus-based gene therapy research (21 papers), PI3K/AKT/mTOR signaling in cancer (20 papers), Cancer Research and Treatments (16 papers), Peptidase Inhibition and Analysis (16 papers) and Ubiquitin and proteasome pathways (15 papers). The work is most often cited by research in Oncology (9.0k citations), Cancer Research (3.9k citations), Molecular Biology (10.9k citations), Radiology, Nuclear Medicine and Imaging (2.8k citations) and Immunology and Allergy (739 citations). Dihua Yu has collaborated with scholars based in United States, China and Taiwan. Frequent co-authors include Mien‐Chie Hung, Yi Xiao, Ming Tan, Gabriel N. Hortobágyi, Lin Zhang, Francisco J. Esteva, Siyuan Zhang, Xiaoyan Zhou, Keng‐Hsueh Lan and Kristine S. Klos. Their work appears in journals such as Cancer Research, Oncogene, Cancer, Cancer Cell and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.